This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Plaque Psoriasis
and you are
over 18
years old
0
This is an early phase trial to investigate
how or whether the drug affects your body.
Show me locations

The purpose

IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into the skin can increase the numbers of T cells and also inflammatory DCs that produce cytokines involved in IL-17 production. Thus, the investigators hypothesize that the dendritic cells present in the skin after IFN-g injection polarize IL-17-producing T cells.

Provided treatments

  • Drug: Actimmune

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01317017. The sponsor of the trial is Rockefeller University and it is looking for 2 volunteers for the current phase.
Official trial title:
Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients